Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio A B, Gómez C, Muñoz F L, Pazo R, Rivera F
Servicio de Oncología Médica, Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain.
Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain.
Clin Transl Oncol. 2016 Dec;18(12):1179-1186. doi: 10.1007/s12094-016-1577-y. Epub 2016 Nov 29.
Esophageal cancer (EC) is an aggressive tumor that represents the 6th most common cause of cancer death worldwide. The estimated incidence in Spain is 2090 cases/year. Two main pathological subtypes exist, squamous cell carcinoma and adenocarcinoma. The main differences between them are localization and underlying factors which are the principal cause of the recent incidence changes observed in west countries. Staging techniques and treatment options which combine surgery, chemotherapy and radiotherapy, reflected the high complexity of the EC management. An undeniably multidisciplinary approach is, therefore, required. In this guide, we review the status of current diagnosis and treatment, define evidence and propose recommendations.
食管癌(EC)是一种侵袭性肿瘤,是全球第六大常见癌症死亡原因。西班牙的估计发病率为每年2090例。主要存在两种病理亚型,即鳞状细胞癌和腺癌。它们之间的主要区别在于定位和潜在因素,这些是西方国家近期发病率变化的主要原因。结合手术、化疗和放疗的分期技术和治疗选择,反映了食管癌管理的高度复杂性。因此,无疑需要采取多学科方法。在本指南中,我们回顾了当前诊断和治疗的现状,明确了证据并提出了建议。